February 5th 2018



Dear Freedom of Information Team,

**Implementation of NICE Technology Appraisal Guidance (TAG)**

I am writing on behalf of Royal National Institute of Blind People (RNIB) to access information under the Freedom of Information Act 2000. This request relates to our work around preventing avoidable sight loss.

Please note that this request relates to secondary care ophthalmology services.

Many thanks in advance for your assistance.

1. **Access to NICE approved treatments in ophthalmology**

Is the treatment listed below routinely available to patients according to it’s NICE TAG?

Please could you indicate by putting a cross in the applicable box below and sending the completed table back to RNIB (contact details below). Confirmation (i.e. indicating ‘yes’) means that patients do not have to use Individual Funding Requests to access aflibercept for treating choroidal neovascularisation.

Please put a cross in the relevant box:

|  |  |  |
| --- | --- | --- |
|  | Yes | No |
| Aflibercept for treating choroidal neovascularisationTechnology appraisal guidance [TA486] Published date: 01 November 2017 | **X** |  |

Please acknowledge receipt of this request by email and your full response to puja.joshi@rnib.org.uk. Please do not hesitate to contact me if you have any questions.

Links to the NICE guideline on this treatment has been copied below my email signature.

Yours sincerely,

****

Puja Joshi

Research Manager

Royal National Institute of Blind People

TouchBase Pears, Bristol Road, Selly Oak, Birmingham

B29 6NA

Email: puja.joshi@rnib.org.uk

Aflibercept for treating choroidal neovascularisation

Technology appraisal guidance [TA486] Published date: 01 November 2017

<https://www.nice.org.uk/guidance/ta486>